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Abstract
Background: Methylation of the tumor suppressor gene H-cadherin (CDH13) has been reported in many cancers.
However, the clinical effect of the CDH13 methylation status of patients with bladder cancer remains to be clarified.
Methods: A systematic literature search was performed to identify eligible studies in the PubMed, Embase, EBSCO,
CKNI and Wanfang databases. The pooled odds ratio (OR) and the corresponding 95 % confidence interval (95 % CI)
was calculated and summarized.
Results: Nine eligible studies were included in the present meta-analysis consisting of a total of 1017 bladder cancer
patients and 265 non-tumor controls. A significant association was found between CDH13 methylation levels and
bladder cancer (OR = 21.71, P < 0.001). The results of subgroup analyses based on sample type suggested that CDH13
methylation was significantly associated with bladder cancer risk in both the tissue and the urine (OR = 53.94, P < 0.001;
OR = 7.71, P < 0.001; respectively). A subgroup analysis based on ethnic population showed that the OR value of
methylated CDH13 was higher in Asians than in Caucasians (OR = 35.18, P < 0.001; OR = 8.86, P < 0.001; respectively).
The relationships between CDH13 methylation and clinicopathological features were also analyzed. A significant
association was not observed between CDH13 methylation status and gender (P = 0.053). Our results revealed that
CDH13 methylation was significantly associated with high-grade bladder cancer, multiple bladder cancer and muscle
invasive bladder cancer (OR = 2.22, P < 0.001; OR = 1.45, P = 0.032; OR = 3.42, P < 0.001; respectively).
Conclusion: Our study indicates that CDH13 methylation may play an important role in the carcinogenesis,
development and progression of bladder cancer. In addition, CDH13 methylation has the potential to be a useful
biomarker for bladder cancer screening in urine samples and to be a prognostic biomarker in the clinic.
Keywords: CDH13 methylation, Bladder cancer, Screening, Biomarker
Abbreviations: CDH13, H-cadherin; CI, Confidence interval; MIBC, Muscle invasive bladder cancer; OR, Odds ratio;
TCC, Transitional cell carcinoma; TNM, Tumor/node/metastasis.
Background
Human bladder cancer is the most common urinary
system malignancy in the world. According to global
cancer statistics, approximately 74,000 cases of bladder
cancer will be diagnosed in the USA in 2015, leading to
an estimated 16,000 deaths [1]. Bladder cancer consists
of three histological and pathological types: urothelial
carcinoma, squamous cell carcinoma and adenocarcin-
oma. Urothelial carcinoma, also known as transitional
cell carcinoma (TCC), is the most common type,
accounting for 90 % of all bladder cancer cases [2, 3].
Clinically, studies have shown that non-muscle invasive
bladder cancer (stages Ta – T1) accounts for approxi-
mately 70–80 % of all cases, with the remainder being
characterized as muscle invasive bladder cancer (stages
T2–T4). Furthermore, 10–30 % of non-muscle invasive
bladder cancer (NMIBC) will progress to muscle
invasive bladder cancer (MIBC) [4, 5]. MIBC patients
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have a much worse outcome with regards to tumor
recurrence and progression, with a 5-year survival rate
of 25–60 % [6–8]. Thus, additional noninvasive
biomarkers for the prediction and diagnosis of bladder
cancer are needed in the clinic.
Epigenetic changes are early and frequent events in
cancer that play an important role in carcinogenesis.
DNA methylation is the most common epigenetic
alteration in human cancers [9–11]. The detection of
aberrantly methylated genes can be used as a diagnostic
or prognostic biomarker for human cancers, especially
when the aberrant methylation silences tumor suppres-
sor genes [12–14]. The CDH13 gene, located on 16q24,
encodes a protein that belongs to the cadherin family
[15]. CDH13, a tumor suppressor gene (TSG), is also
called H-cadherin or T-cadherin and plays a pivotal role
in cell–cell adhesion [16]. The expression of CDH13 in
human tumor cells can inhibit their invasive potential
and markedly reduce their proliferation [17–19]. CDH13
promoter methylation has been reported in some human
cancers including bladder cancer [16].
However, the association between CDH13 promoter
methylation and bladder cancer remains to be clarified. In
this study, a meta-analysis was conducted to evaluate the
effect of CDH13 methylation on the clinicopathological
features of patients with bladder cancer.
Methods
Search strategy
A systemic literature search for studies published prior
to November 16, 2015 was conducted in the PubMed,
Embase, EBSCO, CKNI and Wanfang databases without
any language restrictions. The following keywords and
search terms were used: (CDH13 OR cadherin 13 OR
H-cadherin OR T-cadherin) AND (bladder cancer OR
bladder tumor OR bladder carcinoma OR bladder
neoplasm) AND (methylation OR epigenetic silencing).
The reference lists of the retrieved articles and reviews
were then manually searched to identify potentially
relevant studies.
Inclusion criteria
The eligible studies met the following criteria: 1) the
patients were diagnosed with bladder cancer based on
histopathology; 2) CDH13 methylation was evaluated in
different types of samples, such as tissue, serum, plasma
and urine; 3) regarding control samples by cystoscopy
and histopathological confirmation, tissue samples
belonged to normal tissues, while fluid samples such as
serum, plasma or urine were from healthy individuals or
patients with benign urological diseases; 4) the studies
showed the associations between CDH13 methylation
and clinicopathological parameters, including gender
(male vs female), cancer tumor/node/metastasis (TNM)
stage (T2/T4 vs Ta/T1), grade (grade 3 vs grade1/2) or
tumor number (multiple vs single); 5) the methylation
frequency of the CDH13 gene was sufficient for the
case-control or cohort studies; 6) the studies were
published in English or Chinese. The studies that were
excluded did not meet our inclusion criteria. When the
authors published more than one paper using the same
sample data, either the most recent study or the study
using the largest sample size was selected. The current
meta-analysis was reported based on the Preferred
Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement.
Data extraction
The following pieces of information from the eligible
studies were collected: first author surname, year of
publication, ethnicity, histological type, types of samples,
detection method, number of samples, clinicopathologi-
cal parameters, gender, stage, grade, tumor number,
frequency of CDH13 methylation, etc. As a control
group, our meta-analysis used non-cancerous samples
including non-cancerous diseases of the bladder and
normal healthy tissue, according to each individual study
in the original literature. Of these studies, a tumor stage
of ≤ 1 was defined as early stage, a tumor stage of ≥ 2
was defined as advanced stage, a tumor grade of ≤ 2 was
defined as low-grade, and a tumor grade of 3 was
defined as high-grade. The final eligible studies were
independently assessed by two reviewers for the current
meta-analysis.
Data analysis
The analysis was conducted using STATA 12.0 (Stata
Corporation) to evaluate the relationships between
CDH13 methylation and bladder cancer via the pooled
odds ratio (OR) and the corresponding 95 % confidence
interval (95 % CI). The frequency of CDH13 methylation
was analyzed according to various cancer characteristics.
A statistical test for heterogeneity was performed based
on the chi-square test and Q statistic [20]. If substantial
heterogeneity (I2 ≥ 50 % or p < 0.1) was observed, a
random-effects model was used to calculate the parame-
ters. Otherwise, a fixed effects model assuming a lack of
heterogeneity was used [21, 22]. Egger’s test was used to
evaluate for possible publication bias [23]. A p value of
less than 0.05 was considered statistically significant.
Results
Study characteristics
The search method described above obtained 49
potentially relevant articles. We carefully reviewed the
titles, abstracts and full-texts of the articles. In total, 9
published studies (English, 7; Chinese, 2) met the inclu-
sion criteria of the present meta-analysis [24–32] and
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included 1017 bladder cancer patients and 265 controls,
as shown in Fig. 1. Of these studies, 8 studies assessed
the association between CDH13 methylation and bladder
cancer risk, 5 studies evaluated the relationship between
CDH13 methylation and gender, 5 studies explored the
association between CDH13 methylation and tumor
number, 4 studies reported the tumor grade (grade 3 vs
grade 1-2), and 5 studies evaluated the effect of clinical
stage (T2-T4 vs Ta-T1). The main characteristics of the
included studies were presented in Table 1.
CDH13 methylation and the risk of bladder caner
The heterogeneity among the studies was not significant
(p = 0.495 and I2 = 0.0 %), and therefore, the fixed effects
model was used. The OR value of CDH13 methylation in
bladder cancer patients compared with non-tumor
controls was 21.71 (95 % CI: 9.83–47.94, P < 0.001) (Fig. 2);
this analysis included 920 bladder cancer patients and 265
controls. Subgroup analyses were performed to investigate
the difference in CDH13 methylation according to sample
type (tissue and urine) and ethnicity (Caucasians and
Asians) (Table 2). The results showed that the pooled
OR value for the tissue group was higher than that of
the urine group (OR = 53.94, 95 % CI = 12.83–226.87,
P < 0.001; OR = 7.71, 95 % CI = 2.65–22.39, P < 0.001;
respectively). The subgroup analysis according to
ethnic populations revealed that the OR value of meth-
ylated CDH13 in Asians was higher than in Caucasians
Fig. 1 Flow diagram of the literature search strategy and the assessment of the identified studies
Table 1 Basic characteristics of the studies included in the current meta-analysis
Methylation % Number Gender Grade Stage Tumor number
First author Year Ethnicity Method Sample Case Control Cases Controls Male Female 3 1-2 ≥2 ≤1 Multiple Single
Maruyama et al. 2001 Caucasians MSP Tissue 29.9 % - 97 - - - 65 32 - - - -
Meng et al. 2007 Asians MSP Urine 15.2 % 0 % 92 30 - - - - 27 65 - -
Yu et al. 2007 Asians MSP Urine 16.7 % 0 % 132 30 - - - - - - - -
Cabello et al. 2011 Caucasians * Urine 27.1 % 6 % 96 50 - - 36 60 18 78 - -
Agundez et al. 2011 Caucasians * Tissue 62.6 % 0 % 91 10 82 9 - - - - 44 47
Lin et al. 2011 Asians MSP Serum 30.7 % 0 % 127 41 88 39 31 96 49 78 74 53
Lin et al. 2012 Asians MSP Tissue 35.3 % 0 % 133 43 94 39 37 96 48 85 82 51
Lin et al. 2013 Asians MSP Tissue 60.6 % 0 % 71 23 49 22 - - 32 39 43 28
Lin et al. 2014 Asians MSP Tissue 44.9 % 0 % 178 38 124 54 - - - - 76 102
MSP methylation-specific polymerase chain reaction, “-” indicates data not available
*indicates MS-MLPA (Methylation-Specific Multiplex Ligation-Dependent Probe Amplification)
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(OR = 35.18, 95 % CI = 11.20–110.55, P < 0.001; OR =
8.86, 95 % CI = 2.91–27.03, P < 0.001; respectively).
The relationships between CDH13 methylation and
clinicopathological features
The associations between CDH13 methylation and
clinicopathological features were analyzed, as shown in
Table 3. The analyses of CDH13 methylation and gender,
tumor grade and tumor number used the random effects
model, while a fixed effects model was used for tumor
stage. A significant association was not found between
CDH13 methylation and gender in the 5 studies ana-
lyzed (OR = 1.46, 95 % CI = 0.99–2.15, P = 0.053), which
included 437 male patients and 163 female patients
(Fig. 3). The pooled OR from 5 studies including 174
advanced bladder cancer patients and 345 early stage
bladder cancer patients indicated that CDH13 methyla-
tion was significantly higher in advanced stage tumors
than in early stage tumors (OR = 3.42, 95 % CI =
1.72–6.80, P < 0.001) (Fig. 4). Results from 4 studies
comparing a total of 169 high-grade patients and 284
low-grade patients showed that CDH13 methylation was
significantly associated with high-grade bladder cancer
(OR = 2.22, 95 % CI = 1.72–6.80, P < 0.001) (Fig. 5).
Results from 5 studies analyzing a total of 319 bladder
cancer patients with multiple tumors and 281 bladder
cancer patients with single tumors demonstrated that
methylated CDH13 was significantly associated with pa-
tients harboring multiple tumors (OR = 1.45, 95 % CI =
1.03–2.04, P = 0.032) (Fig. 6).
Fig. 2 Forest plot of the association between CDH13 methylation and bladder cancer from a fixed-effects model, including 8 studies with 920
bladder cancer patients and 265 controls, OR = 21.71, 95 % CI: 9.83–47.94, P < 0.001
Table 2 Summary of the relationship between CDH13 methylation and bladder cancer
Studies Overall OR (95 % CI) I2; p P value Cases Controls p (Egger’s test)
Total 8 21.71 (9.83–47.94) 0.0 %; 0.495 <0.001 920 265 0.008
Material:
Urine 3 7.71 (2.65–22.39) 0.0 %; 0.831 <0.001 320 110
Tissue 4 53.94 (12.83–226.87) 0.0 %; 0.986 <0.001 473 114
Race:
Caucasians 2 8.86 (2.91–27.03) 24.0 %; 0.251 <0.001 187 60
Asians 6 35.18 (11.20–110.55) 0.0 %; 0.903 <0.001 733 205
CDH13 H-cadherin, OR odds ratio, CI confidence interval
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Significant heterogeneity was found in relation to
tumor stage in cancer (I2 = 59.0 %, p = 0.045). Thus, a
sensitivity analysis by omitting a single study was carried
out to assess the stability of the pooled OR. When we
removed this study by Lin 2011 et al. [25], the heterogen-
eity was significantly decreased, with the absence of
heterogeneity (I2 = 14.7 %, p = 0.318). However, the pooled
OR of CDH13 promoter methylation was not significantly
changed (OR = 2.75, 95 % = 1.71–4.44, P < 0.001), suggest-
ing the stability of our analyses.
Publication bias
Egger’s test was performed to assess for publication
bias of the included studies (Tables 2 and 3). Egger’s
Table 3 The correlations between CDH13 methylation and clinicopathological features
Studies Overall OR (95 % CI) I2; p P value p (Egger’s test) Patients
Gender Male Female
5 1.46 (0.99–2.15) 0.0 %; 0.496 0.053 0.085 437 163
Grade High-grade Low-grade
4 2.22 (1.43–3.43) 0.0 %; 0.641 <0.001 0.613 169 284
Stage MIBC NMIBC
5 3.42 (1.72–6.80) 59.0 %; 0.045 <0.001 0.279 174 345
Number Multiple Single
5 1.45 (1.03–2.04) 0.0 %; 0.779 0.032 0.038 319 281
MIBC muscle invasive bladder cancer (stages T2–T4), NMIBC non-muscle invasive bladder cancer (stages Ta – T1), low-grade tumor grade ≤ 2, high-grade tumor
grade of 3
Fig. 3 Forest plot of the association between CDH13 methylation and gender from a fixed-effects model, including 5 studies with 437 male
patients and 163 female patients, OR = 1.46, 95 % CI = 0.99–2.15, P = 0.053
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test provided strong statistical evidence for a publica-
tion bias in the comparison between CDH13 methyla-
tion of bladder cancer patients and non-tumor controls
(p = 0.008). The relatively small number of control
samples (265 controls versus 920 bladder cancer pa-
tients) may cause publication bias. Egger’s test indi-
cated a lack of publication bias in the current analysis
of CDH13 methylation status and clinicopathological
features (p > 0.05). Egger’s funnel plot of the publica-
tion bias test for CDH13 methylation was shown in
Additional file 1: Table S1.
Discussion
DNA methylation in the blood, sputum, urine, feces,
and other bodily fluids can be used as a non-invasive
biomarker for the early detection of various cancers
[12, 33, 34]. Aberrant methylation of the CDH13 gene
has been reported in many cancers, including non-
small cell lung cancer [35], breast cancer [36], gastric
cancer [37], and colorectal carcinoma [38]. However,
the potential of CDH13 gene methylation to be a bio-
marker for bladder cancer has not yet been evaluated.
The methylation rate of CDH13 gene was relatively
lower in non-tumor control samples, with a mean
methylation frequency of 1.1 % in this study. The find-
ings of the current study showed that CDH13 promoter
methylation was significantly higher in bladder cancer
patients than in non-tumor control samples (OR =
21.71, P < 0.001), suggesting that the methylation of
CDH13 may be involved in the development of bladder
cancer. No significant heterogeneity was observed in
cancer vs. controls (p = 0.495 and I2 = 0.0 %), indicating
the reliability of our results. In addition, the result of a
subgroup analysis based on sample type suggested that
the CDH13 methylation status was significant in both tis-
sue and urine samples (OR = 53.94, P < 0.001; OR = 7.71,
P < 0.001; respectively), indicating that the detection of
CDH13 methylation has the potential to be a non-invasive
biomarker in the urine, which may aid in the early screen-
ing for and the diagnosis of bladder cancer. The OR value
in Asians (OR = 35.18, P < 0.001) was significantly higher
than in Caucasians (OR = 8.86, P < 0.001), which revealed
that CDH13 methylation may be a relatively more import-
ant risk factor among Asian populations.
Fig. 4 Forest plot of the association between CDH13 methylation and tumor grade from a fixed-effects model, including 4 studies with 169
high-grade patients and 284 low-grade patients, OR = 2.22, 95 % CI = 1.72–6.80, P < 0.001
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In addition, we conducted meta-analyses to determine
the correlations between CDH13 methylation and clini-
copathological characteristics. The results showed that
the CDH13 methylation status was not associated with
gender (OR = 1.46, 95 % CI = 0.99–2.15, P = 0.053). The
levels of methylated CDH13 were significantly higher in
muscle invasive bladder cancer (stages T2–T4) than in
non-muscle invasive bladder cancer (stages Ta – T1)
(OR = 3.42, P < 0.001). CDH13methylation status was sig-
nificantly associated with high-grade (grade 3) bladder
cancer (OR = 2.22, P < 0.001). The levels of methylated
CDH13 were significantly higher in bladder cancer con-
sisting of multiple tumors than in bladder cancer consist-
ing of a single tumor (OR = 1.45, P = 0.032). Patients with
multiple tumors, high-grade bladder cancer, or muscle
invasive bladder cancer are characterized by a high
incidence of recurrence and progression and a poorer
outcome [39, 40]. Our findings indicated that CDH13 pro-
moter methylation was a very useful biomarker that can
predict the recurrence of bladder cancer.
Some limitations of the current meta-analysis should
be considered. First, the inclusion of articles published
only in English and Chinese might lead to a selection
bias. Second, the primary ethnic population of the
patients in the current study was Asian, while only two
studies involving Caucasians were involved in this meta-
analysis. Other ethnicities, such as Africans, were
limited. Third, due to the limitation of eligible studies in
fluid samples, we did not further evaluate the diagnostic
capacity of CDH13 promoter methylation for patients
with non-muscle invasive bladder cancer. Thus, more
studies based on urine and blood samples are very
essential to evaluate whether CDH13 promoter methyla-
tion can become a noninvasive biomarker for the
detection and diagnosis of non-muscle invasive bladder
cancer in the future. Therefore, additional studies
incorporating larger sample sizes are required to confirm
our results in the future.
Conclusion
Our study indicates that CDH13 methylation may play a
key role in the initiation and progression of bladder can-
cer, especially among Asian populations. In addition,
CDH13 methylation has the potential to become a useful
Fig. 5 Forest plot of the correlation between CDH13 methylation and tumor stage from a random-effects model, including 5 studies with 174
advanced bladder cancer patients and 345 early stage bladder cancer patients, OR = 3.42, 95 % CI = 1.72–6.80, P < 0.001
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biomarker for the clinical screening of bladder cancer in
the urine. CDH13 methylation may also be a prognostic
biomarker for patients with tumor progression.
Additional file
Additional file 1: Table S1. Egger’s funnel plot of the publication bias
test for CDH13 methylation. (DOCX 21 kb)
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